To provide accurate non-invasive means of monitoring LN disease activity and response to LN therapy, we discovered and validated a urine biomarker panel consisting of 6 urine proteins: neutrophil gelatinase–associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), kidney injury molecule-1 (KIM-1), ceruloplasmin, adiponectin, and hemopexin. The gene discussed is ADIPOQ; the disease is lobular neoplasia.